leukemia

cytogenetic, and molecular remissions in the majority of patients. The distinction between complete hematologic response (CHR), complete cytogenetic response (CCyR), and major molecular response (MMR) is critical for long-term disease control. However, resistanc

ment, offering high rates of durable remission. Current Therapeutic Approaches Purine Nucleoside Analogues: Cladribine remains the frontline therapy, 1. achieving complete remission in over 80% of patients. Its administration is typically a single 5- to 7-day cour